/PRNewswire/ OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer
Trishula TherapeuticsJanuary 21, 2021 GMT Trishula Continues to Advance Development of TTX-030 in collaboration with AbbVie
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) Today Trishula Therapeutics, Inc., a clinical stage, privately held company developing TTX-030, a first-in-class anti-CD39 antibody in advanced cancers, announced the appointment of Anil Singhal, Ph.D., MBA, as Chief Executive Officer, effective immediately. Dr. Singhal will also serve on the Trishula Board of Directors.
“The Board of Directors of Trishula Therapeutics is thrilled to bring Anil to the company with his stellar track record in advancing novel oncology therapies from early clinical development through to approval,” said Luke Evnin, Ph.D., Chairman of Trishula’s Board of Directors. “We have complete confidenc